Fig. 2From: Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximabDistribution of FCGR and BAFF promoter gene polymorphisms in the patients who developed late-onset neutropenia (LON) during follow-up and the matched control patients who did not (non-LON). BAFF B-cell-activating factorBack to article page